{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:37:42Z","timestamp":1758098262661,"version":"3.44.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10787-025-01894-9","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:47:22Z","timestamp":1755186442000},"page":"5173-5189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transforming advancing autosomal dominant polycystic kidney disease care: investigating new horizons in treatment and research"],"prefix":"10.1007","volume":"33","author":[{"given":"Komal","family":"Thapa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heena","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarjot","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1590","authenticated-orcid":false,"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"issue":"1","key":"1894_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/ana.25635","volume":"87","author":"N Adotevi","year":"2020","unstructured":"Adotevi N, Lewczuk E, Sun H, Joshi S, Dabrowska N, Shan S, Williamson J, Kapur J (2020) \u03b1-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor plasticity sustains severe, fatal status epilepticus. Ann Neurol 87(1):84\u201396","journal-title":"Ann Neurol"},{"issue":"2","key":"1894_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/ckj\/sfac236","volume":"16","author":"H Ali","year":"2022","unstructured":"Ali H, Naim M, Senum SR, AlSahow A, Bahbahani Y, Abu-Farha M, Abubaker J, Mohammad A, Al-Hunayan A, Asbeutah AM, Zayed M, Devarajan S, Hussain N, John SE, Channanath A, Thanaraj TA, Al-Ali M, AlMousawi M, Al-Mulla F, Harris PC (2022) The genetic landscape of autosomal dominant polycystic kidney disease in Kuwait. Clin Kidney J 16(2):355\u2013366. https:\/\/doi.org\/10.1093\/ckj\/sfac236","journal-title":"Clin Kidney J"},{"key":"1894_CR3","doi-asserted-by":"publisher","first-page":"120675","DOI":"10.1016\/j.lfs.2022.120675","volume":"303","author":"TM Al-Noshokaty","year":"2022","unstructured":"Al-Noshokaty TM, Mesbah NM, Abo-Elmatty DM, Abulsoud AI, Abdel-Hamed AR (2022) Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-\u03baB pathways and LncRNA-AF085935\/GPC3 axis. Life Sci 303:120675. https:\/\/doi.org\/10.1016\/j.lfs.2022.120675","journal-title":"Life Sci"},{"issue":"9","key":"1894_CR4","doi-asserted-by":"publisher","first-page":"100691","DOI":"10.1016\/j.xkme.2023.100691","volume":"5","author":"S Amin","year":"2023","unstructured":"Amin S, Sangadi I, Allman-Farinelli M, Badve SV, Boudville N, Coolican H, Coulshed S, Foster S, Fernando M, Haloob I, Harris DC (2023) Participant perceptions in a long-term clinical trial of autosomal dominant polycystic kidney disease. Kidney Med 5(9):100691. https:\/\/doi.org\/10.1016\/j.xkme.2023.100691","journal-title":"Kidney Med"},{"key":"1894_CR5","doi-asserted-by":"publisher","first-page":"101271","DOI":"10.1016\/j.redox.2019.101271","volume":"26","author":"J Angulo","year":"2019","unstructured":"Angulo J, El Assar M, Sevilleja-Ortiz A, S\u00e1nchez-Ferrer A, Romero-Otero J, Mart\u00ednez-Salamanca JI, La Fuente JM, Rodr\u00edguez-Ma\u00f1as L (2019) Short-term pharmacological activation of Nrf2 ameliorates vascular dysfunction in aged rats and in pathological human vasculature. A potential target for therapeutic intervention. Redox Biol 26:101271. https:\/\/doi.org\/10.1016\/j.redox.2019.101271","journal-title":"Redox Biol"},{"key":"1894_CR6","doi-asserted-by":"publisher","first-page":"102220","DOI":"10.1016\/j.plefa.2020.102220","volume":"164","author":"HM Aukema","year":"2021","unstructured":"Aukema HM (2021) Prostaglandins as potential targets for the treatment of polycystic kidney disease. Prostaglandins Leukot Essent Fatty Acids 164:102220. https:\/\/doi.org\/10.1016\/j.plefa.2020.102220","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"9","key":"1894_CR7","doi-asserted-by":"publisher","first-page":"8391","DOI":"10.3390\/ijms24098391","volume":"24","author":"SC Badoiu","year":"2023","unstructured":"Badoiu SC, Greabu M, Miricescu D, Stanescu-Spinu II, Ilinca R, Balan DG, Balcangiu-Stroescu AE, Mihai DA, Vacaroiu IA, Stefani C, Jinga V (2023) PI3K\/AKT\/mTOR dysregulation and reprogramming metabolic pathways in renal cancer: crosstalk with the VHL\/HIF axis. Int J Mol Sci 24(9):8391. https:\/\/doi.org\/10.3390\/ijms24098391","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1894_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1128\/mcb.00099-20","volume":"6","author":"PN Baird","year":"2020","unstructured":"Baird PN, Saw SM, Lanca C, Guggenheim JA, Smith EL III, Zhou X, Matsui KO, Wu PC, Sankaridurg P, Chia A, Rosman M (2020) Myopia. Nat Rev Disease Primers 6(1):99. https:\/\/doi.org\/10.1128\/mcb.00099-20","journal-title":"Nat Rev Disease Primers"},{"issue":"13","key":"1894_CR112","doi-asserted-by":"publisher","first-page":"e00099-20","DOI":"10.1128\/MCB.00099-20","volume":"40","author":"L Baird","year":"2020","unstructured":"Baird L, Yamamoto M (2020) The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol Cell Biol 40(13):e00099-20. https:\/\/doi.org\/10.1128\/MCB.00099-20","journal-title":"Mol Cell Biol"},{"issue":"12","key":"1894_CR9","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/ph16121702","volume":"16","author":"D Baroni","year":"2023","unstructured":"Baroni D, Scarano N, Ludovico A, Brandas C, Parodi A, Lunaccio D, Fossa P, Moran O, Cichero E, Millo E (2023) In silico and in vitro evaluation of the mechanism of action of three VX809-based hybrid derivatives as correctors of the f508del cftr protein. Pharmaceuticals 16(12):1702. https:\/\/doi.org\/10.3390\/ph16121702","journal-title":"Pharmaceuticals"},{"issue":"2","key":"1894_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s0092-8674(02)00716-x","volume":"109","author":"AK Bhunia","year":"2002","unstructured":"Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, Germino FJ, Germino GG (2002) PKD1 induces p21waf1 and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 109(2):157\u2013168. https:\/\/doi.org\/10.1016\/s0092-8674(02)00716-x","journal-title":"Cell"},{"issue":"12","key":"1894_CR11","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.3390\/cells11121938","volume":"11","author":"C Braccia","year":"2022","unstructured":"Braccia C, Christopher JA, Crook OM, Breckels LM, Queiroz RM, Liessi N, Tomati V, Capurro V, Bandiera T, Baldassari S, Pedemonte N (2022) CFTR rescue by Lumacaftor (VX-809) induces an extensive reorganization of mitochondria in the cystic fibrosis bronchial epithelium. Cells 11(12):1938. https:\/\/doi.org\/10.3390\/cells11121938","journal-title":"Cells"},{"issue":"Apr","key":"1894_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1134\/S1990519X22020031","volume":"16","author":"AS Brovkina","year":"2022","unstructured":"Brovkina AS, Ushakov RE, Vassilieva IO, Domnina AP, Burova EB (2022) Involvement of the PI3K\/Akt\/mTOR pathway in controlling chondrogenic differentiation of endometrial mesenchymal stromal cells. Cell Tissue Biol 16(Apr):130\u2013139. https:\/\/doi.org\/10.1134\/S1990519X22020031","journal-title":"Cell Tissue Biol"},{"issue":"13","key":"1894_CR13","doi-asserted-by":"publisher","first-page":"9295","DOI":"10.1021\/acs.jmedchem.2c00567","volume":"65","author":"X Cao","year":"2022","unstructured":"Cao X, Wang P, Yuan H, Zhang H, He Y, Fu K, Fang Q, Liu H, Su L, Yin L, Xu P (2022) Benzodiazepine derivatives as potent vasopressin V2 receptor antagonists for the treatment of autosomal dominant kidney disease. J Med Chem 65(13):9295\u20139311","journal-title":"J Med Chem"},{"key":"1894_CR14","unstructured":"Celentano S, Capolongo G, Pollastro R (2019) Bardoxolone: a new potential therapeutic agent in the treatment of autosomal dominant polycystic kidney disease?. Giornale Italiano Nefrol Organo Ufficiale Della Soc Italiana Nefrol, 36(5)"},{"issue":"15","key":"1894_CR15","doi-asserted-by":"publisher","first-page":"8499","DOI":"10.3390\/ijms23158499","volume":"23","author":"MY Chang","year":"2022","unstructured":"Chang MY, Hsu SH, Ma LY, Chou LF, Hung CC, Tian YC, Yang CW (2022) Effects of suramin on polycystic kidney disease in a mouse model of polycystin-1 deficiency. Int J Mol Sci 23(15):8499. https:\/\/doi.org\/10.3390\/ijms23158499","journal-title":"Int J Mol Sci"},{"key":"1894_CR16","doi-asserted-by":"publisher","first-page":"154478","DOI":"10.1016\/j.phymed.2022.154478","volume":"108","author":"MY Chen","year":"2023","unstructured":"Chen MY, Hsu CH, Setiawan SA, Tzeng DT, Ma HP, Ong JR, Chu YC, Hsieh MS, Wu AT, Tzeng YM, Yeh CT (2023) Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK\/Akt-mTOR signaling axis. Phytomedicine 108:154478. https:\/\/doi.org\/10.1016\/j.phymed.2022.154478","journal-title":"Phytomedicine"},{"key":"1894_CR17","doi-asserted-by":"publisher","first-page":"108373","DOI":"10.1016\/j.pharmthera.2023.108373","volume":"244","author":"I Costa","year":"2023","unstructured":"Costa I, Barbosa DJ, Benfeito S, Silva V, Chavarria D, Borges F, Remi\u00e3o F, Silva R (2023) Molecular mechanisms of ferroptosis and their involvement in brain diseases. Pharmacol Ther 244:108373. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108373","journal-title":"Pharmacol Ther"},{"issue":"6","key":"1894_CR18","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1053\/j.ajkd.2018.02.347","volume":"71","author":"NM Cruz","year":"2018","unstructured":"Cruz NM, Freedman BS (2018) CRISPR gene editing in the kidney. Am J Kidney Dis 71(6):874\u2013883","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1894_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.kint.2023.01.026","volume":"103","author":"PG Dagorn","year":"2023","unstructured":"Dagorn PG, Buchholz B, Kraus A, Batchuluun B, Bange H, Blockken L, Steinberg GR, Moller DE, Hallakou-Bozec S (2023) A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of autosomal dominant polycystic kidney disease. Kidney Int 103(5):917\u2013929. https:\/\/doi.org\/10.1016\/j.kint.2023.01.026","journal-title":"Kidney Int"},{"key":"1894_CR20","doi-asserted-by":"publisher","first-page":"690247","DOI":"10.3389\/fphys.2021.690247","volume":"12","author":"A Della Sala","year":"2021","unstructured":"Della Sala A, Prono G, Hirsch E, Ghigo A (2021) Role of protein kinase A-mediated phosphorylation in CFTR channel activity regulation. Front Physiol 12:690247","journal-title":"Front Physiol"},{"issue":"1","key":"1894_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/ijms21010183","volume":"21","author":"A Di Mise","year":"2019","unstructured":"Di Mise A, Venneri M, Ranieri M, Centrone M, Pellegrini L, Tamma G, Valenti G (2019) Lixivaptan, a new generation diuretic, counteracts vasopressin-induced aquaporin-2 trafficking and function in renal collecting duct cells. Int J Mol Sci 21(1):183","journal-title":"Int J Mol Sci"},{"key":"1894_CR22","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100774R","author":"A Di Mise","year":"2021","unstructured":"Di Mise A, Wang X, Ye H, Pellegrini L, Torres VE, Valenti G (2021) Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease. FASEB J. https:\/\/doi.org\/10.1096\/fj.202100774R","journal-title":"FASEB J"},{"issue":"1","key":"1894_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ki.2011.296","volume":"81","author":"LX Fan","year":"2012","unstructured":"Fan LX, Li X, Magenheimer B, Calvet JP, Li X (2012) Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int 81(1):76\u201385. https:\/\/doi.org\/10.1038\/ki.2011.296","journal-title":"Kidney Int"},{"issue":"4","key":"1894_CR24","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3390\/cancers15041197","volume":"15","author":"B Fibbi","year":"2023","unstructured":"Fibbi B, Marroncini G, Naldi L, Anceschi C, Errico A, Norello D, Peri A (2023) Hyponatremia and cancer: from bedside to benchside. Cancers 15(4):1197","journal-title":"Cancers"},{"key":"1894_CR25","doi-asserted-by":"publisher","first-page":"1179582","DOI":"10.3389\/fphys.2023.1179582","volume":"14","author":"I Gareev","year":"2023","unstructured":"Gareev I, Ahmad A, Wang J, Beilerli A, Ilyasova T, Sufianov A, Beylerli O (2023) Gastric juice non-coding RNAs as potential biomarkers for gastric cancer. Front Physiol 14:1179582. https:\/\/doi.org\/10.3389\/fphys.2023.1179582","journal-title":"Front Physiol"},{"issue":"4","key":"1894_CR26","doi-asserted-by":"publisher","first-page":"E744","DOI":"10.1152\/ajpendo.00228.2020","volume":"319","author":"F Gonz\u00e1lez","year":"2020","unstructured":"Gonz\u00e1lez F, Mather KJ, Considine RV, Abdelhadi OA, Acton AJ (2020) Salicylate administration suppresses the inflammatory response to nutrients and improves ovarian function in polycystic ovary syndrome. Am J Physiol Endocrinol Metab 319(4):E744\u2013E752","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"1894_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms14395","volume":"8","author":"S Hajarnis","year":"2017","unstructured":"Hajarnis S, Lakhia R, Yheskel M, Williams D, Sorourian M, Liu X, Aboudehen K, Zhang S, Kersjes K, Galasso R, Li J (2017) microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism. Nat Commun 8(1):1\u20135","journal-title":"Nat Commun"},{"issue":"3","key":"1894_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ekir.2022.11.019","volume":"8","author":"KR Hallows","year":"2023","unstructured":"Hallows KR, Abebe KZ, Li H, Saitta B, Althouse AD, Bae KT, Lalama CM, Miskulin DC, Perrone RD, Seliger SL, Watnick TJ (2023) Association of longitudinal urinary metabolic biomarkers with ADPKD severity and response to metformin in TAME-PKD clinical trial participants. Kidney Int Rep 8(3):467\u2013477. https:\/\/doi.org\/10.1016\/j.ekir.2022.11.019","journal-title":"Kidney Int Rep"},{"issue":"9","key":"1894_CR29","doi-asserted-by":"publisher","first-page":"931475","DOI":"10.3389\/fcvm.2022.931475","volume":"26","author":"Y Han","year":"2022","unstructured":"Han Y, Nie J, Wang DW, Ni L (2022) Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors. Front Cardiovasc Med 26(9):931475","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"1894_CR30","doi-asserted-by":"publisher","first-page":"e12487","DOI":"10.1002\/rmb2.12487","volume":"21","author":"M Harada","year":"2022","unstructured":"Harada M (2022) Pathophysiology of polycystic ovary syndrome revisited: current understanding and perspectives regarding future research. Reprod Med Biol 21(1):e12487","journal-title":"Reprod Med Biol"},{"issue":"2","key":"1894_CR31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2215\/CJN.0000000000000055","volume":"18","author":"MC Hogan","year":"2023","unstructured":"Hogan MC, Masyuk TV (2023) Concurrent targeting of vasopressin receptor 2 and somatostatin receptors in autosomal dominant polycystic kidney disease: a promising approach for autosomal dominant polycystic kidney disease treatment? Clin J Am Soc Nephrol 18(2):154\u2013156","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1894_CR32","doi-asserted-by":"publisher","first-page":"F305","DOI":"10.1152\/ajprenal.00081.2021","volume":"321","author":"A Hus-Citharel","year":"2021","unstructured":"Hus-Citharel A, Bouby N, Corbani M, Mion J, Mendre C, Darusi J, Tomboly C, Trueba M, Serradeil-Le Gal C, Llorens-Cortes C, Guillon G (2021) Characterization of a functional V1B vasopressin receptor in the male rat kidney: evidence for cross talk between V1B and V2 receptor signaling pathways. Am J Physiol Renal Physiol 321(3):F305\u2013F321. https:\/\/doi.org\/10.1152\/ajprenal.00081.2021","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"1894_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40779-023-00468-6","volume":"10","author":"BM Hussen","year":"2023","unstructured":"Hussen BM, Rasul MF, Abdullah SR, Hidayat HJ, Faraj GS, Ali FA, Salihi A, Baniahmad A, Ghafouri-Fard S, Rahman M, Glassy MC (2023) Targeting miRNA by CRISPR\/Cas in cancer: advantages and challenges. Mil Med Res 10(1):32. https:\/\/doi.org\/10.1186\/s40779-023-00468-6","journal-title":"Mil Med Res"},{"issue":"2","key":"1894_CR34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41581-022-00648-y","volume":"19","author":"C Huynh","year":"2023","unstructured":"Huynh C, Ryu J, Lee J, Inoki A, Inoki K (2023) Nutrient-sensing mTORC1 and AMPK pathways in chronic kidney diseases. Nat Rev Nephrol 19(2):102\u2013122. https:\/\/doi.org\/10.1038\/s41581-022-00648-y","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"1894_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/MNH.0000000000000556","volume":"29","author":"M Ito","year":"2020","unstructured":"Ito M, Tanaka T, Nangaku M (2020) Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases. Curr Opin Nephrol Hypertens 29(1):128\u2013135","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1894_CR36","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jconrel.2022.07.027","volume":"349","author":"JM Jim\u00e9nez-Morales","year":"2022","unstructured":"Jim\u00e9nez-Morales JM, Hern\u00e1ndez-Cuenca YE, Reyes-Abrahantes A, Ruiz-Garc\u00eda H, Barajas-Olmos F, Garc\u00eda-Ortiz H, Orozco L, Qui\u00f1ones-Hinojosa A, Reyes-Gonz\u00e1lez J, del Abrahantes-P\u00e9rez MC (2022) MicroRNA delivery systems in glioma therapy and perspectives: a systematic review. J Control Release 349:712\u2013730. https:\/\/doi.org\/10.1016\/j.jconrel.2022.07.027","journal-title":"J Control Release"},{"key":"1894_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41392-023-01559-5","volume":"8","author":"J Jing","year":"2023","unstructured":"Jing J, Wu Z, Wang J, Luo G, Lin H, Fan Y, Zhou C (2023) Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies. Signal Transduct Target Ther 8:315. https:\/\/doi.org\/10.1038\/s41392-023-01559-5","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"1894_CR38","doi-asserted-by":"publisher","first-page":"8582","DOI":"10.3390\/ijms23158582","volume":"23","author":"FF Jubaidi","year":"2022","unstructured":"Jubaidi FF, Zainalabidin S, Taib IS, Abdul Hamid Z, Mohamad Anuar NN, Jalil J, Mohd Nor NA, Budin SB (2022) The role of PKC-MAPK signalling pathways in the development of hyperglycemia-induced cardiovascular complications. Int J Mol Sci 23(15):8582. https:\/\/doi.org\/10.3390\/ijms23158582","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1894_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.krcp.2012.07.002","volume":"31","author":"HJ Kim","year":"2012","unstructured":"Kim HJ, Edelstein CL (2012) Mammalian target of rapamycin inhibition in polycystic kidney disease: from bench to bedside. Kidney Res Clin Practice 31(3):132\u2013138","journal-title":"Kidney Res Clin Practice"},{"issue":"1","key":"1894_CR40","first-page":"36","volume":"11","author":"M Kokolo","year":"2022","unstructured":"Kokolo M, Bach-Elias M (2022) P68 RNA helicase (DDX5) required for the formation of various specific and mature miRNA active RISC complexes. Microrna (Shariqah, United Arab Emirates) 11(1):36","journal-title":"Microrna (Shariqah, United Arab Emirates)"},{"key":"1894_CR41","doi-asserted-by":"publisher","unstructured":"Koohgoli RY (2020) Oxylipin profiles in an orthologous mouse model of autosomal dominant polycystic kidney disease. https:\/\/doi.org\/10.1007\/s40620-018-00578-8","DOI":"10.1007\/s40620-018-00578-8"},{"key":"1894_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbi.2016.12.005","volume":"61","author":"M Lagraoui","year":"2017","unstructured":"Lagraoui M, Sukumar G, Latoche JR, Maynard SK, Dalgard CL, Schaefer BC (2017) Salsalate treatment following traumatic brain injury reduces inflammation and promotes a neuroprotective and neurogenic transcriptional response with concomitant functional recovery. Brain Behav Immun 61:96\u2013109","journal-title":"Brain Behav Immun"},{"issue":"1","key":"1894_CR43","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1038\/s41467-022-32543-2","volume":"13","author":"R Lakhia","year":"2022","unstructured":"Lakhia R, Ramalingam H, Chang CM, Cobo-Stark P, Biggers L, Flaten A, Alvarez J, Valencia T, Wallace DP, Lee EC, Patel V (2022) PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression. Nat Commun 13(1):4765. https:\/\/doi.org\/10.1038\/s41467-022-32543-2","journal-title":"Nat Commun"},{"issue":"1","key":"1894_CR44","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","volume":"10","author":"EC Lee","year":"2019","unstructured":"Lee EC, Valencia T, Allerson C, Schairer A, Flaten A, Yheskel M, Kersjes K, Li J, Gatto S, Takhar M, Lockton S (2019) Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun 10(1):4148. https:\/\/doi.org\/10.1038\/s41467-019-11918-y","journal-title":"Nat Commun"},{"issue":"1","key":"1894_CR45","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/biomedicines12010116","volume":"12","author":"I Legaz","year":"2024","unstructured":"Legaz I, Jimenez-Coll V, Gonz\u00e1lez-L\u00f3pez R, Fern\u00e1ndez-Gonz\u00e1lez M, Alegr\u00eda-Marcos MJ, Gali\u00e1n JA, Botella C, Moya-Quiles R, Muro-P\u00e9rez M, Minguela A, Llorente S (2024) Micrornas as potential graft rejection or tolerance biomarkers and their dilemma in clinical routines behaving like devilish, angelic, or frightening elements. Biomedicines 12(1):116. https:\/\/doi.org\/10.3390\/biomedicines12010116","journal-title":"Biomedicines"},{"key":"1894_CR46","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","volume":"47","author":"WN Leonhard","year":"2019","unstructured":"Leonhard WN, Song X, Kanhai AA, Iliuta IA, Bozovic A, Steinberg GR, Peters DJ, Pei Y (2019) Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine 47:436\u2013445. https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.041","journal-title":"EBioMedicine"},{"issue":"1","key":"1894_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","volume":"3","author":"Q Li","year":"2022","unstructured":"Li Q, Li Z, Luo T, Shi H (2022) Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy. Mol Biomed 3(1):47","journal-title":"Mol Biomed"},{"issue":"2","key":"1894_CR48","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41401-022-00937-z","volume":"44","author":"XW Li","year":"2023","unstructured":"Li XW, Ran JH, Zhou H, He JZ, Qiu ZW, Wang SY, Wu MN, Zhu S, An YP, Ma A, Li M (2023) 1-indanone retards cyst development in ADPKD mouse model by stabilizing tubulin and down-regulating anterograde transport of cilia. Acta Pharmacol Sin 44(2):406\u2013420","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"1894_CR49","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.3390\/ijms24076053","volume":"24","author":"DW Lin","year":"2023","unstructured":"Lin DW, Hsu YC, Chang CC, Hsieh CC, Lin CL (2023) Insights into the molecular mechanisms of NRF2 in kidney injury and diseases. Int J Mol Sci 24(7):6053. https:\/\/doi.org\/10.3390\/ijms24076053","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1894_CR50","doi-asserted-by":"publisher","first-page":"113514","DOI":"10.1016\/j.yexcr.2023.113514","volume":"425","author":"B Liu","year":"2023","unstructured":"Liu B, Qu X, Wang J, Xu L, Zhang L, Xu B, Su J, Bian X (2023) LINC00365 functions as a tumor suppressor by inhibiting HIF-1\u03b1-mediated glucose metabolism reprogramming in breast cancer. Exp Cell Res 425(1):113514. https:\/\/doi.org\/10.1016\/j.yexcr.2023.113514","journal-title":"Exp Cell Res"},{"issue":"1","key":"1894_CR51","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1002\/pdi3.16","volume":"1","author":"Y Lu","year":"2023","unstructured":"Lu Y, Song Y, Sun S, Zhang L, Chen Y (2023) Gene therapy for pediatric genetic kidney diseases. Pediatr Discov 1(1):e16. https:\/\/doi.org\/10.1002\/pdi3.16","journal-title":"Pediatr Discov"},{"issue":"2","key":"1894_CR52","first-page":"140","volume":"4","author":"B Lucke-Wold","year":"2017","unstructured":"Lucke-Wold B, Seidel K, Udo R, Omalu B, Ornstein M, Nolan R et al (2017) Role of tau acetylation in Alzheimer\u2019s disease and chronic traumatic encephalopathy: the way forward for successful treatment. J Neurol Neurosurg 4(2):140","journal-title":"J Neurol Neurosurg"},{"issue":"11","key":"1894_CR53","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1681\/ASN.2018121274","volume":"30","author":"M Ma","year":"2019","unstructured":"Ma M, Legu\u00e9 E, Tian X, Somlo S, Liem KF Jr (2019) Cell-autonomous hedgehog signaling is not required for cyst formation in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 30(11):2103\u20132111","journal-title":"J Am Soc Nephrol"},{"key":"1894_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.11.046","author":"TB Malas","year":"2020","unstructured":"Malas TB, Leonhard WN, Bange H, Granchi Z, Hettne KM, Van Westen GJ, Price LS, Hoen PAC\u2019t, Peters DJ (2020) Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles. Ebio Med. https:\/\/doi.org\/10.1016\/j.ebiom.2019.11.046","journal-title":"Ebio Med"},{"key":"1894_CR55","doi-asserted-by":"publisher","first-page":"1163288","DOI":"10.3389\/fimmu.2023.1163288","volume":"14","author":"A Mazzieri","year":"2023","unstructured":"Mazzieri A, Basta G, Calafiore R, Luca G (2023) GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway. Front Immunol 14:1163288. https:\/\/doi.org\/10.3389\/fimmu.2023.1163288","journal-title":"Front Immunol"},{"issue":"1","key":"1894_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.kint.2021.10.014","volume":"101","author":"YR Mehta","year":"2022","unstructured":"Mehta YR, Lewis SA, Leo KT, Chen L, Park E, Raghuram V, Chou CL, Yang CR, Kikuchi H, Khundmiri S, Poll BG (2022) \u201cADPKD-omics\u201d: determinants of cyclic AMP levels in renal epithelial cells. Kidney Int 101(1):47\u201362","journal-title":"Kidney Int"},{"issue":"19","key":"1894_CR57","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1001\/jama.2018.15870","volume":"320","author":"E Meijer","year":"2018","unstructured":"Meijer E, Visser FW, Van Aerts RM, Blijdorp CJ, Casteleijn NF, D\u2019Agnolo HM, Dekker SE, Drenth JP, de Fijter JW, Van Gastel MD, Gevers TJ (2018) Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial. JAMA 320(19):2010\u20132019. https:\/\/doi.org\/10.1001\/jama.2018.15870","journal-title":"JAMA"},{"issue":"1","key":"1894_CR58","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1038\/s41598-021-85416-x","volume":"11","author":"Y Mitsuhata","year":"2021","unstructured":"Mitsuhata Y, Abe T, Misaki K, Nakajima Y, Kiriya K, Kawasaki M, Kiyonari H, Takeichi M, Toya M, Sato M (2021) Cyst formation in proximal renal tubules caused by dysfunction of the microtubule minus-end regulator CAMSAP3. Sci Rep 11(1):5857. https:\/\/doi.org\/10.1038\/s41598-021-85416-x","journal-title":"Sci Rep"},{"key":"1894_CR59","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1055\/a-2111-6649","volume":"73","author":"K Nagai","year":"2023","unstructured":"Nagai K, Fukuno S, Miura T, Yasuda-Imanishi E, Konishi H (2023) Altered gene expression of cytochrome P450 and ABC transporter in human hepatocellular carcinoma HepG2 cells exposed to bardoxolone methyl. Drug Res 73:473\u2013475. https:\/\/doi.org\/10.1055\/a-2111-6649","journal-title":"Drug Res"},{"key":"1894_CR60","doi-asserted-by":"publisher","first-page":"124581","DOI":"10.1016\/j.ijbiomac.2023.124581","volume":"242","author":"M Nandave","year":"2023","unstructured":"Nandave M, Acharjee R, Bhaduri K, Upadhyay J, Rupanagunta GP, Ansari MN (2023) A pharmacological review on SIRT 1 and SIRT 2 proteins, activators, and inhibitors: call for further research. Int J Biol Macromol 242:124581. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.124581","journal-title":"Int J Biol Macromol"},{"issue":"27","key":"1894_CR61","doi-asserted-by":"publisher","first-page":"13320","DOI":"10.1073\/pnas.1822113116","volume":"116","author":"F Omar","year":"2019","unstructured":"Omar F, Findlay JE, Carfray G, Allcock RW, Jiang Z, Moore C, Muir AL, Lannoy M, Fertig BA, Mai D, Day JP (2019) Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. Proc Natl Acad Sci USA 116(27):13320\u201313329. https:\/\/doi.org\/10.1073\/pnas.1822113116","journal-title":"Proc Natl Acad Sci USA"},{"key":"1894_CR62","doi-asserted-by":"publisher","first-page":"122329","DOI":"10.1016\/j.biomaterials.2023.122329","volume":"302","author":"R Pala","year":"2023","unstructured":"Pala R, Barui AK, Mohieldin AM, Zhou J, Nauli SM (2023) Folate conjugated nanomedicines for selective inhibition of mTOR signaling in polycystic kidneys at clinically relevant doses. Biomaterials 302:122329. https:\/\/doi.org\/10.1016\/j.biomaterials.2023.122329","journal-title":"Biomaterials"},{"key":"1894_CR63","doi-asserted-by":"publisher","first-page":"109497","DOI":"10.1016\/j.cellsig.2019.109497","volume":"67","author":"MI Parker","year":"2020","unstructured":"Parker MI, Nikonova AS, Sun D, Golemis EA (2020) Proliferative signaling by ERBB proteins and RAF\/MEK\/ERK effectors in polycystic kidney disease. Cell Signal 67:109497. https:\/\/doi.org\/10.1016\/j.cellsig.2019.109497","journal-title":"Cell Signal"},{"issue":"5","key":"1894_CR64","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.kint.2022.05.028","volume":"102","author":"SC Parnell","year":"2022","unstructured":"Parnell SC, Raman A, Zhang Y, Daniel EA, Dai Y, Khanna A, Reif GA, Vivian JL, Fields TA, Wallace DP (2022) Expression of active B-raf proto-oncogene in kidney collecting ducts induces cyst formation in normal mice and accelerates cyst growth in mice with polycystic kidney disease. Kidney Int 102(5):1103\u20131114. https:\/\/doi.org\/10.1016\/j.kint.2022.05.028","journal-title":"Kidney Int"},{"key":"1894_CR65","doi-asserted-by":"publisher","first-page":"378919","DOI":"10.1101\/378919","volume":"2","author":"F Patera","year":"2018","unstructured":"Patera F, Cudzich-Mardy A, Huang Z, Fragiadaki M (2018) Curcumin inhibits cystogenesis in autosomal dominant polycystic kidney disease cells via altering JAK2\/STAT3 activity. bioRxiv 2:378919. https:\/\/doi.org\/10.1101\/378919","journal-title":"bioRxiv"},{"issue":"1","key":"1894_CR66","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1038\/s41598-019-41106-3","volume":"9","author":"F Patera","year":"2019","unstructured":"Patera F, Cudzich-Madry A, Huang Z, Fragiadaki M (2019) Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis. Sci Rep 9(1):4491. https:\/\/doi.org\/10.1038\/s41598-019-41106-3","journal-title":"Sci Rep"},{"key":"1894_CR67","doi-asserted-by":"crossref","unstructured":"Pawnikar S, Magenheimer BS, Munoz EN, Haldane A, Maser RL, Miao Y (2024) Activation of polycystin-1 signaling by binding of stalk-derived peptide agonists. bioRxiv","DOI":"10.7554\/eLife.95992.1"},{"issue":"6","key":"1894_CR69","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1158\/1541-7786.MCR-21-0923","volume":"20","author":"J Peng","year":"2022","unstructured":"Peng J, Ma Y, Zhao X, Yang X, Wang H (2022) Constitutive \u03b2-catenin overexpression represses lncRNA MIR100HG transcription via HDAC6-mediated histone modification in colorectal cancer. Mol Cancer Res 20(6):949\u2013959","journal-title":"Mol Cancer Res"},{"key":"1894_CR70","first-page":"2020","volume":"28","author":"JY Pu","year":"2020","unstructured":"Pu JY, Zhang Y, Wang LX, Wang J, Zhou JH (2020) Inhibition of USP4 attenuates epithelial-mesenchymal transition of renal tubular epithelial cells by T\u03b2RI. bioRxiv 28:2020\u20132110","journal-title":"bioRxiv"},{"issue":"1","key":"1894_CR71","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/antiox11010038","volume":"11","author":"Z Qiu","year":"2021","unstructured":"Qiu Z, He J, Shao G, Hu J, Li X, Zhou H, Li M, Yang B (2021) Obacunone retards renal cyst development in autosomal dominant polycystic kidney disease by activating NRF2. Antioxidants 11(1):38","journal-title":"Antioxidants"},{"issue":"6","key":"1894_CR72","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.3390\/ijms23063317","volume":"23","author":"J Reiterov\u00e1","year":"2022","unstructured":"Reiterov\u00e1 J, Tesa\u0159 V (2022) Autosomal dominant polycystic kidney disease: from pathophysiology of cystogenesis to advances in the treatment. Int J Mol Sci 23(6):3317. https:\/\/doi.org\/10.3390\/ijms23063317","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1894_CR73","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00335-016-9633-z","volume":"49","author":"T Richards","year":"2021","unstructured":"Richards T, Modarage K, Malik SA, Goggolidou P (2021) The cellular pathways and potential therapeutics of polycystic kidney disease. Biochem Soc Trans 49(3):1171\u20131188. https:\/\/doi.org\/10.1007\/s00335-016-9633-z","journal-title":"Biochem Soc Trans"},{"issue":"12","key":"1894_CR74","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1089\/hum.2019.127","volume":"30","author":"JD Rubin","year":"2019","unstructured":"Rubin JD, Nguyen TV, Allen KL, Ayasoufi K, Barry MA (2019) Comparison of gene delivery to the kidney by adenovirus, adeno-associated virus, and lentiviral vectors after intravenous and direct kidney injections. Hum Gene Ther 30(12):1559\u20131571. https:\/\/doi.org\/10.1089\/hum.2019.127","journal-title":"Hum Gene Ther"},{"key":"1894_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-022-01745-9","volume":"26","author":"AK Saini","year":"2020","unstructured":"Saini AK, Saini R, Singh S (2020) Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects. Mol Med 26:1\u20137. https:\/\/doi.org\/10.1007\/s40265-022-01745-9","journal-title":"Mol Med"},{"issue":"20","key":"1894_CR76","doi-asserted-by":"publisher","first-page":"e15058","DOI":"10.14814\/phy2.15058","volume":"9","author":"G Schena","year":"2021","unstructured":"Schena G, Carmosino M, Chiurlia S, Onuchic L, Mastropasqua M, Maiorano E, Schena FP, Caplan MJ (2021) \u03b23 adrenergic receptor as potential therapeutic target in ADPKD. Physiol Rep 9(20):e15058","journal-title":"Physiol Rep"},{"issue":"2","key":"1894_CR77","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1681\/ASN.2018010039","volume":"30","author":"R Schreiber","year":"2019","unstructured":"Schreiber R, Buchholz B, Kraus A, Schley G, Scholz J, Ousingsawat J, Kunzelmann K (2019) Lipid peroxidation drives renal cyst growth in vitro through activation of TMEM16A. J Am Soc Nephrol 30(2):228\u2013242","journal-title":"J Am Soc Nephrol"},{"key":"1894_CR78","doi-asserted-by":"publisher","first-page":"937580","DOI":"10.3389\/fcell.2022.937580","volume":"10","author":"S Shang","year":"2023","unstructured":"Shang S, Wang C, Chen L, Shen W, Xie Y, Li W, Li Q (2023) Novel method for the genomic analysis of PKD1 mutation in autosomal dominant polycystic kidney disease. Front Cell Develop Biol 10:937580. https:\/\/doi.org\/10.3389\/fcell.2022.937580","journal-title":"Front Cell Develop Biol"},{"issue":"1","key":"1894_CR79","doi-asserted-by":"publisher","first-page":"113614","DOI":"10.1016\/j.yexcr.2023.113614","volume":"428","author":"A Sharma","year":"2023","unstructured":"Sharma A, Anand SK, Singh N, Dwivedi UN, Kakkar P (2023) AMP-activated protein kinase: an energy sensor and survival mechanism in the reinstatement of metabolic homeostasis. Exper Cell Res 428(1):113614. https:\/\/doi.org\/10.1016\/j.yexcr.2023.113614","journal-title":"Exper Cell Res"},{"issue":"5","key":"1894_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11011-025-01623-9","volume":"40","author":"A Sharma","year":"2025","unstructured":"Sharma A, Mannan A, Singh S, Singh TG (2025) A second act for spironolactone: cognitive benefits in renal dysfunction\u2013a critical review. Metab Brain Dis 40(5):1\u201315","journal-title":"Metab Brain Dis"},{"issue":"7","key":"1894_CR81","doi-asserted-by":"publisher","first-page":"1098612X2311853","DOI":"10.1177\/1098612x231185393","volume":"25","author":"F Shitamori","year":"2023","unstructured":"Shitamori F, Nonogaki A, Motegi T, Matsumoto Y, Sakamoto M, Tanizawa Y, Nakamura Y, Yonezawa T, Momoi Y, Maeda S (2023) Large-scale epidemiological study on feline autosomal dominant polycystic kidney disease and identification of novel PKD1 gene variants. J Feline Med Surg 25(7):1098612X231185393. https:\/\/doi.org\/10.1177\/1098612x231185393","journal-title":"J Feline Med Surg"},{"issue":"1","key":"1894_CR82","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1038\/s41598-018-23341-2","volume":"8","author":"LM Silva","year":"2018","unstructured":"Silva LM, Jacobs DT, Allard BA, Fields TA, Sharma M, Wallace DP, Tran PV (2018) Inhibition of Hedgehog signaling suppresses proliferation and microcyst formation of human autosomal dominant polycystic kidney disease cells. Sci Rep 8(1):4985. https:\/\/doi.org\/10.1038\/s41598-018-23341-2","journal-title":"Sci Rep"},{"key":"1894_CR111","doi-asserted-by":"publisher","unstructured":"Smith AO, Jonassen JA, Preva KM, Davis RJ, Pazour GJ (2021) c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease. PLoS Genetics 17(12):e1009711. https:\/\/doi.org\/10.1371\/journal.pgen.1009711","DOI":"10.1371\/journal.pgen.1009711"},{"key":"1894_CR83","first-page":"62","volume":"3","author":"AO Smith","year":"2022","unstructured":"Smith AO (2022) Defining the role of c-Jun N-terminal kinase (JNK) signaling in autosomal dominant polycystic kidney disease (doctoral dissertation). J Cell Signal 3:62","journal-title":"J Cell Signal"},{"issue":"4","key":"1894_CR84","doi-asserted-by":"publisher","first-page":"F492","DOI":"10.1152\/ajprenal.00095.2022","volume":"323","author":"SV Sundar","year":"2022","unstructured":"Sundar SV, Zhou JX, Magenheimer BS, Reif GA, Wallace DP, Georg GI, Jakkaraj SR, Tash JS, Yu AS, Li X, Calvet JP (2022) The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease. Am J Physiol Renal Physiol 323(4):F492-506.S. https:\/\/doi.org\/10.1152\/ajprenal.00095.2022","journal-title":"Am J Physiol Renal Physiol"},{"issue":"21","key":"1894_CR85","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1093\/hmg\/ddr338","volume":"20","author":"A Takakura","year":"2011","unstructured":"Takakura A, Nelson EA, Haque N, Humphreys BD, Zandi-Nejad K, Frank DA, Zhou J (2011) Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Human Mol Genetics 20(21):4143\u20134154","journal-title":"Human Mol Genetics"},{"key":"1894_CR86","doi-asserted-by":"publisher","first-page":"119843","DOI":"10.1016\/j.lfs.2021.119843","volume":"282","author":"K Thapa","year":"2021","unstructured":"Thapa K, Singh TG, Kaur A (2021) Cyclic nucleotide phosphodiesterase inhibition as a potential therapeutic target in renal ischemia reperfusion injury. Life Sci 282:119843","journal-title":"Life Sci"},{"issue":"4","key":"1894_CR87","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jphs.2022.02.003","volume":"148","author":"K Tonum","year":"2022","unstructured":"Tonum K, Chabang N, Fongsupa S, Chantawarin S, Jiarpinitnun C, Tuchinda P, Soodvilai S (2022) Pinostrobin inhibits renal CFTR-mediated Cl\u2212 secretion and retards cyst growth in cell-derived cyst and polycystic kidney disease rats. J Pharmacol Sci 148(4):369\u2013376. https:\/\/doi.org\/10.1016\/j.jphs.2022.02.003","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"1894_CR88","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2796.2006.01743.x","volume":"261","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC (2007) Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med 261(1):17\u201331. https:\/\/doi.org\/10.1111\/j.1365-2796.2006.01743.x","journal-title":"J Intern Med"},{"issue":"10","key":"1894_CR89","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1681\/asn.2013070735","volume":"25","author":"PV Tran","year":"2014","unstructured":"Tran PV, Talbott GC, Turbe-Doan A, Jacobs DT, Schonfeld MP, Silva LM, Chatterjee A, Prysak M, Allard BA, Beier DR (2014) Downregulating hedgehog signaling reduces renal cystogenic potential of mouse models. J Am Soc Nephrol 25(10):2201\u20132212. https:\/\/doi.org\/10.1681\/asn.2013070735","journal-title":"J Am Soc Nephrol"},{"issue":"100","key":"1894_CR90","doi-asserted-by":"publisher","first-page":"110488","DOI":"10.1016\/j.cellsig.2022.110488","volume":"1","author":"C Vadivalagan","year":"2022","unstructured":"Vadivalagan C, Krishnan A, Chen SJ, Hseu YC, Muthu S, Dhar R, Aljabali AA, Tambuwala MM (2022) The Warburg effect in osteoporosis: cellular signaling and epigenetic regulation of energy metabolic events to targeting the osteocalcin for phenotypic alteration. Cell Signal 1(100):110488. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110488","journal-title":"Cell Signal"},{"issue":"4","key":"1894_CR91","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1089\/dna.2021.1050","volume":"41","author":"C Wang","year":"2022","unstructured":"Wang C, Zhang Y (2022) Endoplasmic reticulum stress: a new research direction for polycystic ovary syndrome? DNA Cell Biol 41(4):356\u2013367","journal-title":"DNA Cell Biol"},{"issue":"6","key":"1894_CR92","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1159\/000500667","volume":"49","author":"X Wang","year":"2019","unstructured":"Wang X, Constans MM, Chebib FT, Torres VE, Pellegrini L (2019) Effect of a vasopressin V2 receptor antagonist on polycystic kidney disease development in a rat model. Am J Nephrol 49(6):487\u2013493. https:\/\/doi.org\/10.1159\/000500667","journal-title":"Am J Nephrol"},{"issue":"20","key":"1894_CR93","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1042\/cs20210821","volume":"135","author":"L Wilson","year":"2021","unstructured":"Wilson L, Pollard AE, Penfold L, Muckett PJ, Whilding C, Bohlooly-Y M, Wilson P, Carling D (2021) Chronic activation of AMP-activated protein kinase leads to early-onset polycystic kidney phenotype. Clin Sci 135(20):2393\u20132408. https:\/\/doi.org\/10.1042\/cs20210821","journal-title":"Clin Sci"},{"issue":"1","key":"1894_CR94","doi-asserted-by":"publisher","first-page":"14151","DOI":"10.1038\/s41598-017-14083-8","volume":"7","author":"YM Woo","year":"2017","unstructured":"Woo YM, Kim DY, Koo NJ, Kim YM, Lee S, Ko JY, Shin Y, Kim BH, Mun H, Choi S, Lee EJ (2017) Profiling of miRNAs and target genes related to cystogenesis in ADPKD mouse models. Sci Rep 7(1):14151. https:\/\/doi.org\/10.1038\/s41598-017-14083-8","journal-title":"Sci Rep"},{"key":"1894_CR95","doi-asserted-by":"publisher","first-page":"921631","DOI":"10.3389\/fmed.2022.921631","volume":"9","author":"J Xu","year":"2022","unstructured":"Xu J, Xue C, Wang X, Zhang L, Mei C, Mao Z (2022) Chromatin methylation abnormalities in autosomal dominant polycystic kidney disease. Front Med 9:921631. https:\/\/doi.org\/10.3389\/fmed.2022.921631","journal-title":"Front Med"},{"key":"1894_CR96","doi-asserted-by":"publisher","first-page":"690627","DOI":"10.3389\/fcvm.2021.690627","volume":"8","author":"Y Yan","year":"2021","unstructured":"Yan Y, Li T, Li Z, He M, Wang D, Xu Y, Yang X, Bai Y, Lao Y, Zhang Z, Wu W (2021) Metformin suppresses the progress of diabetes-accelerated atherosclerosis by inhibition of vascular smooth muscle cell migration through AMPK\u2013Pdlim5 pathway. Front Cardiovasc Med 8:690627. https:\/\/doi.org\/10.3389\/fcvm.2021.690627","journal-title":"Front Cardiovasc Med"},{"key":"1894_CR97","doi-asserted-by":"publisher","first-page":"1071864","DOI":"10.3389\/fmed.2022.1071864","volume":"9","author":"Y Yang","year":"2023","unstructured":"Yang Y, Cheng J, Lin Q, Ni Z (2023) Autophagy-dependent ferroptosis in kidney disease. Front Med 9:1071864","journal-title":"Front Med"},{"issue":"2","key":"1894_CR98","doi-asserted-by":"publisher","first-page":"166987","DOI":"10.1016\/j.bbadis.2023.166987","volume":"1870","author":"SA Yasinoglu","year":"2024","unstructured":"Yasinoglu SA, Kuipers TB, Suidgeest E, van der Weerd L, Mei H, Baelde HJ, Peters DJ (2024) Transcriptomic profiling of polycystic kidney disease identifies paracrine factors in the early cyst microenvironment. Biochim Biophys Acta (BBA) Mol Basis Disease 1870(2):166987. https:\/\/doi.org\/10.1016\/j.bbadis.2023.166987","journal-title":"Biochim Biophys Acta (BBA) Mol Basis Disease"},{"issue":"5","key":"1894_CR99","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1681\/ASN.2015010057","volume":"27","author":"H Ye","year":"2016","unstructured":"Ye H, Wang X, Sussman CR, Hopp K, Irazabal MV, Bakeberg JL, LaRiviere WB, Manganiello VC, Vorhees CV, Zhao H, Harris PC (2016) Modulation of polycystic kidney disease severity by phosphodiesterase 1 and 3 subfamilies. J Am Soc Nephrol 27(5):1312\u20131320","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1894_CR100","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1681\/ASN.2021040460","volume":"32","author":"X Zhang","year":"2021","unstructured":"Zhang X, Li LX, Ding H, Torres VE, Yu C, Li X (2021) Ferroptosis promotes cyst growth in autosomal dominant polycystic kidney disease mouse models. J Am Soc Nephrol 32(11):2759\u20132776","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"1894_CR101","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00726-023-03282-5","volume":"55","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Han H, Qian Y, Wang Q, Jiang M (2023) Advanced glycation end products promote the progression of chronic kidney diseases by targeting calpain 6. Amino Acids 55(7):903\u2013912. https:\/\/doi.org\/10.1007\/s00726-023-03282-5","journal-title":"Amino Acids"},{"issue":"3","key":"1894_CR102","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1002\/mco2.261","volume":"4","author":"Q Zhong","year":"2023","unstructured":"Zhong Q, Xiao X, Qiu Y, Xu Z, Chen C, Chong B, Zhao X, Hai S, Li S, An Z, Dai L (2023) Protein posttranslational modifications in health and diseases: functions, regulatory mechanisms, and therapeutic implications. MedComm 4(3):e261","journal-title":"MedComm"},{"issue":"3","key":"1894_CR103","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1053\/j.akdh.2023.01.003","volume":"30","author":"JX Zhou","year":"2023","unstructured":"Zhou JX, Torres VE (2023a) Autosomal dominant polycystic kidney disease therapies on the horizon. Adv Kidney Disease Health 30(3):245\u2013260. https:\/\/doi.org\/10.1053\/j.akdh.2023.01.003","journal-title":"Adv Kidney Disease Health"},{"issue":"5","key":"1894_CR104","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.kint.2023.02.010","volume":"103","author":"JX Zhou","year":"2023","unstructured":"Zhou JX, Torres VE (2023b) Drug repurposing in autosomal dominant polycystic kidney disease. Kidney Int 103(5):859\u2013871. https:\/\/doi.org\/10.1016\/j.kint.2023.02.010","journal-title":"Kidney Int"},{"issue":"14","key":"1894_CR105","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1093\/hmg\/ddv136","volume":"24","author":"X Zhou","year":"2015","unstructured":"Zhou X, Fan LX, Peters DJ, Trudel M, Bradner JE, Li X (2015) Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD. Human Mol Genetics 24(14):3982\u20133993","journal-title":"Human Mol Genetics"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01894-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01894-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01894-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T04:15:47Z","timestamp":1758082547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01894-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":106,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1894"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01894-9","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"type":"print","value":"0925-4692"},{"type":"electronic","value":"1568-5608"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not disclosed any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}